Plasma Fibroblast Growth Factor 23 as a Predictor for Fosinopril Therapeutic Efficacy in Pediatric Primary Hypertension

BACKGROUND: Plasma fibroblast growth factor 23 (FGF23) has been reported to be a predictive biomarker for therapeutic effectiveness of angiotensin‐converting enzyme inhibitors in heart failure. Higher plasma FGF23 levels have been shown in pediatric primary hypertension, but the predictive value of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yao, Cui, Yaxi, Yuan, Yue, Gao, Lu, Li, Qirui, Huang, Xiaolan, Liu, Yanyan, Shi, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075434/
https://www.ncbi.nlm.nih.gov/pubmed/35322670
http://dx.doi.org/10.1161/JAHA.121.023182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075434/
https://www.ncbi.nlm.nih.gov/pubmed/35322670
http://dx.doi.org/10.1161/JAHA.121.023182

Ejemplares similares